A Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11 (FRIENDS-01)

FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

FRIENDS-01：A Multicenter Open-label Randomized Controlled Study on the Treatment of CTIT of the Efficacy and Safety With Romiplostim N01 Compared to Recombinant Human Interleukin-11

Study Overview

• Status: Recruiting
• Conditions: CTIT: Cancer Therapy Induced Thrombocytopenia
• Intervention / Treatment: Drug: Romiplostim N01; Drug: Recombinant Human Interleukin-11 (rhIL-11)

• Study Type: Interventional
• Enrollment (Estimated): 88
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Xiaofeng Chen Xiaofeng Chen, Chief physician; Phone Number: 86+13585172066; Email: xiaofengch198019@126.com

Study Locations

• China
  • Jiangsu
    • Nanjing, Jiangsu, China, 210000
      • Recruiting
      • The First Affiliated Hospital with Nanjing Medical University
      • Contact: Xiaofeng Chen, Chief physician; Phone Number: 86+13585172066; Email: xiaofengch198019@126.com
      • Principal Investigator: Yongqian Shu, Chief physician
      • Principal Investigator: Xiaofeng Chen, Chief physician

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 1. Voluntarily participate in this study, sign an informed consent form, and strictly complied with the study protocol requirements；
• 2.Age range from 18 to 75 years old，male or female；
• 3.Diagnosed with a malignant tumor by histopathology and/or cytology and is receiving anti-tumor therapy such as chemotherapy, radiotherapy, immunology, and targeting；
• 4.ECOG PS score: 0-2；
• 5.Developed treatment-induced thrombocytopenia with platelet count between 10×10⁹/L and 75×10⁹/L; if platelet count is between 10×10⁹/L and 50×10⁹/L, one platelet test is required with a 24-hour interval; if platelet count is between 50×10⁹/L and 75×10⁹/L, two platelet tests are required.；
• 6.Estimated survival time during screening is ≥ 12 weeks, and could be treated with current antitumor regimens for at least 1 cycle；
• 7.Subjects of childbearing age agree to take reliable contraceptive measures (including male or female condoms, contraceptive foam, contraceptive gel, contraceptive film, contraceptive cream, contraceptive suppository, abstinence and the placement of intrauterine devices, etc.) throughout the study period; Excluding female participants who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation, or more than 1 year after menopause, as well as male participants who have undergone bilateral salpingectomy or ligation；
• 8.Adequate organ and bone marrow function.

Exclusion Criteria:

• 1. Platelet values at screening or baseline were ≤10×10^9/L；
• 2.Participants with a history of any hematological malignancy，including but not limited to leukemia, primary immune thrombocytopenia, myeloproliferative diseases, multiple myeloma, and myelodysplastic syndrome；
• 3.Participants had a history of chronic platelet or bleeding disorders，or screening for thrombocytopenia caused by causes other than CIT within the first 6 months, including but not limited to chronic liver disease, splenic hyperfunction, infection, and bleeding；
• 4.Bone marrow invasion or metastasis;
• 5.Have received pelvic and spinal radiation therapy, as well as bone field radiation therapy, or are currently/expected to receive radiation therapy within the three months prior to screening;
• 6.Brain tumors or brain metastases;
• 7.Screening for a history of severe cardiovascular disease within the first 6 months, such as congestive heart failure (NYHA heart function score III-IV), known arrhythmias that increase the risk of thromboembolism, such as atrial fibrillation, after coronary stent implantation, angioplasty, and coronary artery bypass grafting;
• 8.Any history of arterial or venous thrombosis occurring within the first 6 months of screening;
• 9.Screening for clinical manifestations of severe bleeding within the first two weeks, such as gastrointestinal or central nervous system bleeding;
• 10.Neutrophil absolute value < 1.0 × 10^9/L, hemoglobin < 80g/L, allowing the use of granulocyte colony-stimulating factors and red blood cells that comply with clinical norms EPO infusion therapy
• 11.Significant abnormalities in liver function: patients without liver metastasis, ALT/AST>3ULN (upper limit of normal value), TBIL>3ULN； Patients with liver metastasis are present, ALT/AST≥5ULN，TBIL≥5ULN;
• 12.Renal dysfunction: blood creatinine ≥ 1.5ULN or eGFR ≤ 60 ml/min (Cockcroft Gault formula);
• 13.Received thrombopoietin receptor agonists, recombinant human thrombopoietin (rhTPO), or recombinant human interleukin-11 (rhIL-11) within 5 half-lives of the drug prior to screening. The maximum washout period calculated based on 5 half-lives of the drugs is: hetrombopag 8.4 days, avatrombopag 4 days, eltrombopag 6.7 days, lusutrombopag 6 days, romiplostim or romiplostim N01 29 days, rhTPO 9.7 days, rhIL-11 1.4 days;
• 14.Received platelet transfusion within the first two weeks of randomization;
• 15.Participants who are known or expected to be allergic or intolerant to Roxetine N01 or rhIL-11 excipients;
• 16.HIV infected individuals;
• 17.Pregnant or lactating women;
• 18.Participants had medically known hereditary prethrombotic syndromes (e.g., clotting factor V Leiden mutation, prothrombin G20210A mutation, or hereditary antithrombin III (ATIII) deficiency);
• 19.Participants were given a vitamin K antagonist within 7 days prior to screening (permitted drugs included low molecular weight heparin, Factor Xa inhibitors, or thrombin inhibitors);
• 20.As assessed by the investigators, the participants had any concomitant medical history that could compromise the participants' safe completion of the study, such as unstable angina, renal failure on hemodialysis, or an active infection requiring intravenous antibiotics;
• 21.Participated in any clinical study of any other investigational drug or device three months prior to screening;
• 22.The researchers believe that participating in the trial poses a significant risk to the health or safety of the subjects, or other circumstances that may affect the efficacy evaluation;

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Romiplostim N01; 3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.	Drug: Romiplostim N01; 3.0 µg/kg, subcutaneous injection, once a week. Afterwards, refer to the platelet count evaluated during the visit before the next dosing cycle: ① If the platelet count is less than 50×10^9/L, increase by 1-2μg/kg once a week; ② If the platelet count is between 50-99×10^9/L, increase by 1μg/kg once a week. According to platelet count and symptoms, investigators can adjust the dosage to the maximum dosage of 10μg/kg once a week.
Active Comparator: Recombinant Human Interleukin-11; 25-50μg/kg, subcutaneous injection, once a day	Drug: Recombinant Human Interleukin-11 (rhIL-11); 25-50μg/kg, subcutaneous injection, once a day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The median number of days when the platelet count reaches 100×10^9/L or the absolute platelet count increases by 50×10^9/L	through study completion, an average of 5 months

Secondary Outcome Measures

Outcome Measure	Time Frame
The median number of days for patients with baseline PLT counts less than 50×10^9/L and less than 75×10^9/L to achieve a PLT count of 100×10^9/L	through study completion, an average of 5 months
The median number of days in which thrombocytopenia increases from Grade 3 or 4 to Grade 1 or 2	through study completion, an average of 5 months
The average number of days when the platelet count reaches 100×10^9/L or the absolute platelet count increases by 50×10^9/L	through study completion, an average of 5 months
Proportion of patients with PLT reaching 100×10^9/L or absolute platelet count increase of 50×10^9/L after 1 week of treatment	Within 1 weeks after receiving treatment
Proportion of patients with PLT reaching 100×10^9/L or absolute platelet count increase of 50×10^9/L after 2 weeks of treatment	Within 2 weeks after receiving treatment
Proportion of patients with PLT reaching 100×10^9/L or absolute platelet count increase of 50×10^9/L after 3 weeks of treatment	Within 3 weeks after receiving treatment
Proportion of patients with PLT reaching 100×10^9/L or absolute platelet count increase of 50×10^9/L after 4 weeks of treatment	Within 4 weeks after receiving treatment
Thrombocytopenia level in X+1 cycle of antitumor therapy	through study completion, an average of 5 months
Proportion of bleeding patients	through study completion, an average of 5 months
The incidence of platelet transfusion	through study completion, an average of 5 months
The absolute increase in platelet count after the medication was discontinued	through study completion, an average of 5 months
Effect of Romiplostim N01 on hemoglobin and leukocyte	through study completion, an average of 5 months
Adverse events (evaluated using the Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0), laboratory tests, vital signs, electrocardiograms, and physical examinations, etc	through study completion, an average of 5 months
The incidence and severity of bleeding events ( being evaluated using the WHO Bleeding Scale) should be closely monitored for participants' drug allergies, cardiovascular adverse events, risk of thrombosis, and rhIL-11 related adverse events	through study completion, an average of 5 months

Collaborators and Investigators

• Sponsor: The First Affiliated Hospital with Nanjing Medical University

Study record dates

Study Major Dates

• Study Start (Actual): February 24, 2025
• Primary Completion (Estimated): April 21, 2026
• Study Completion (Estimated): July 21, 2026

Study Registration Dates

• First Submitted: December 29, 2024
• First Submitted That Met QC Criteria: December 29, 2024
• First Posted (Actual): January 6, 2025

Study Record Updates

• Last Update Posted (Actual): April 14, 2026
• Last Update Submitted That Met QC Criteria: April 9, 2026
• Last Verified: May 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cytopenia; Hematologic Diseases; Blood Platelet Disorders; Thrombocytopenia; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors; Intercellular Signaling Peptides and Proteins; Cytokines; Interleukins; Interleukin-11; oprelvekin
• Other Study ID Numbers: QLMA-CTIT-IIT-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No